Indian Pharma Sector Expected To Grow 9-11% In FY22: ICRA

New Delhi :  India’s pharma sector is expected to grow at 9-11% in FY22, rating agency ICRA said on Tuesday.
It attributed the growth to the improving demand for non-Covid products in addition to new product introductions, rupee depreciation, and expanding market coverage.
“Going forward, sustenance of trend in doctor visits and elective surgeries given the news around the Omicron variant, and performance of new launches in addition to revenue growth momentum in the acute segment will remain key monitorables,” ICRA said.
Further, pricing pressures and rising raw material costs are expected to contract margins for the sector to 22.5% in FY22 and further to pre-Covid levels of 21-22% in FY23, said Deepak Jotwani, Assistant Vice President and Sector Head, ICRA.
The outlook for the pharma sector remains ‘Stable’ led by healthy revenue growth and is seen remaining comfortable despite higher capital expenditure and R&D expenses given the robust cash levels.
  • Related Posts

    • Pharma
    • July 10, 2025
    • 97 views
    Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

    India stands tall as a pharmaceutical powerhouse, supplying 20% of the world’s generic medicines and nearly 62% of global vaccines. Yet, this success now faces a storm: US President Donald…

    • Pharma
    • July 10, 2025
    • 93 views
    Novartis wins approval for first malaria drug for newborns and babies

    ZURICH: Novartis (NOVN.S), opens new tab said on Tuesday it had received approval in Switzerland for Coartem Baby, which it said was the first drug to treat malaria in babies…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Very Arty Surgery for Weight Loss by SSI Mantra, World’s First

    Very Arty Surgery for Weight Loss by SSI Mantra, World’s First

    Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

    Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

    Novartis wins approval for first malaria drug for newborns and babies

    Novartis wins approval for first malaria drug for newborns and babies

    Nectar to sell API, formulations & menthol biz to Ceph Lifesciences for Rs 1,290 cr

    Nectar to sell API, formulations & menthol biz to Ceph Lifesciences for Rs 1,290 cr